

Comment on “Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case–control study from Denmark”

Citation for published version (APA):

van Veelen, A., Nielen, J. T. H., van Geel, R., & Croes, S. (2021). Comment on “Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case–control study from Denmark”. *Journal of the American Academy of Dermatology*, 85(6), E357-E357. <https://doi.org/10.1016/j.jaad.2019.01.087>

Document status and date:

Published: 01/12/2021

DOI:

[10.1016/j.jaad.2019.01.087](https://doi.org/10.1016/j.jaad.2019.01.087)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

**Comment on
“Hydrochlorothiazide use and risk
of nonmelanoma skin cancer: A
nationwide case–control study
from Denmark”**



To the Editor: We were intrigued by the findings from a case–control study that showed a minor association between long-term hydrochlorothiazide use and risk of basal cell carcinoma (BCC) and a strong association with squamous cell carcinoma (SCC).¹ The publication played an important role in the decision making on a subsequent warning by the European Medicines Agency.² However, a meta-analysis performed by Gandini et al did not find a significant association between the use of thiazide-diuretics and skin cancer risk (melanoma as well as nonmelanoma).³

The data source used in this case–control study (Danish National Data) might have been suboptimal, considering that an important potential confounder, smoking status, is not available in this database.¹ The study data were not statistically adjusted for smoking status, which is a known risk factor of SCC.⁴ We recognize that the analyses were adjusted for chronic obstructive pulmonary disease; however, this might not reflect smoking status accurately.

Another important issue is the possibility of diagnostic bias. Patients who are treated for a condition for which hydrochlorothiazide is prescribed are likely to visit their general practitioner more often, and consequently, they might be more likely to receive a skin cancer diagnosis. The supplemental tables show increased risk of BCC (bendroflumethiazide, calcium channel blockers, angiotensin II receptor antagonists) and SCC (furosemide) associated with the use of other drug classes as well. Although these increased risks were not as high as those from the main analyses, it should be noted that the supplementary analyses were adjusted for

hydrochlorothiazide use and the main analyses were not adjusted for concomitant use of other antihypertensive drugs. Therefore, we question the association found between hydrochlorothiazide use and risk of BCC and SCC.

Ard van Veelen, PharmD,^{a,b} Johannes T. H. Nielen, PharmD, PhD,^a Robin van Geel, PharmD, PhD,^{a,b} and Sander Croes, PharmD, PhD^{a,b}

From the Department of Clinical Pharmacy and Toxicology^a and CARIM School for Cardiovascular Disease,^b Maastricht University Medical Centre+, Maastricht, the Netherlands.

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Ard van Veelen, P, Debyelaan 25, Maastricht 6229 HX, the Netherlands

E-mail: ard.van.veelen@mumc.nl

REFERENCES

1. Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friss S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. *J Am Acad Dermatol.* 2018;78(4):673-681.
2. European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommendations on signals Available at: https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf; 2018.
3. Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. *Crit Rev Oncol Hematol.* 2018 Feb;122:1-9.
4. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. *Arch Dermatol.* 2012;148(8):939-946.

<https://doi.org/10.1016/j.jaad.2019.01.087>